FDA denies approval to wider use of J&J’s blood clot preventer

The U.S. Food and Drug Administration denied an approval to a wider use of Johnson & Johnson’s heart drug Xarelto.

The blood-clot preventing drug is already approved for use in multiple indications.

J&J’s unit Janssen Research & Development was seeking approval for using the drug to reduce the risk of heart problems, such as heart attack, stroke or death, in patients with acute coronary syndrome and to reduce the risk of stent thrombosis - a blood clot at the site of the stent.

J&J said it was evaluating the contents of the letters and would determine the appropriate next steps.

(Reporting by Esha Dey in Bangalore; Editing by Kirti Pandey)

###

(Reuters)

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

FDA Warns of Potential Risk of Severe Liver Injury With Use of Dronedarone   Statin label to carry diabetes warning   A mobile device for preventing and treating drug use   White House announces plans to reduce prescription drug abuse   Vioxx harmful even after patients stopped taking it   Diabetes drugs warning: they cause heart problems   FDA warns against fake online H1N1 remedy claims   Row brews over ecstasy downgrade call   FDA lacks access to food safety records: Congress   Man says prescription drug caused gambling problem   Rash most common side effect in Vectibix trials   Man jailed for fake Viagra sales